Merck Commits to Veeva Vault CRM for Major Launch Expansion

Reuters
21 Jul
Merck Commits to Veeva Vault CRM for Major Launch Expansion

Veeva Systems Inc. has announced that Merck, also known as MSD outside the United States and Canada, has committed to using Veeva Vault CRM. This strategic move is set to support Merck as it embarks on one of its most significant launch periods, spanning various new therapeutic areas and modalities. Dave Williams, Merck's executive vice president and chief information and digital officer, expressed excitement about expanding the partnership with Veeva, highlighting the shared commitment to customer success. Veeva CEO Peter Gassner praised Merck's leadership in science and expressed honor in extending their partnership to include Vault CRM. The Vault CRM solution, part of the Vault CRM Suite, offers advanced global capabilities tailored to meet unique regional and compliance requirements, enhancing commercial execution across both personal and digital channels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF33661) on July 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10